Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
EMD Serono |
---|---|
Information provided by: | EMD Serono |
ClinicalTrials.gov Identifier: | NCT00367484 |
The objectives of the study are:
- comparison of the incidence and time course of the development of neutralizing antibodies (Nabs) to Rebif after 48 weeks of therapy, to historical data from Serono clinical trial databases to assess the safety and tolerability of Rebif®
Condition | Intervention | Phase |
---|---|---|
Relapsing Remitting Multiple Sclerosis |
Drug: Rebif® |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
Ages Eligible for Study: | 18 Years to 60 Years |
Genders Eligible for Study: | Both |
Inclusion Criteria:
If female, she must either
Exclusion Criteria:
Other concurrent systemic disorders incompatible with the study (at the Investigator’s discretion).
Study ID Numbers: | 24810 |
Study First Received: | August 21, 2006 |
Last Updated: | June 11, 2007 |
ClinicalTrials.gov Identifier: | NCT00367484 |
Health Authority: | France: Institutional Ethical Committee |
Autoimmune Diseases Multiple Sclerosis Demyelinating Diseases Interferon beta 1a Demyelinating Autoimmune Diseases, CNS |
Demyelinating diseases Sclerosis Multiple Sclerosis, Relapsing-Remitting Autoimmune Diseases of the Nervous System |
Pathologic Processes Immune System Diseases Nervous System Diseases |